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Atvstract Exposure of neuronal cells to the chronic presence of 
opiates leads to a complex series of biochemical events which 
reflect the changes that result in tolerance and dependence in 
animals. To achieve a better understanding of the molecular 
mechanisms underlying these processes, we have examined the 
effect of agonist efficacy on the regulation of the fi-opioid recep- 
tor mRNA in NGI08-15 cells. Incubation with various opiates 
decreased receptor numbers in the order of their efficacy. North- 
ern blot analysis showed that there are 4 size classes of mRNA 
coding for the 6-opioid receptor in NGI08-15 cells even though 
only one known protein species is found. Moreover, the amount 
of each transcript is coordinately decreased by long-term etor- 
phine treatment, but not necessarily to the same extent. The 
etorphine-indnced ecrease in receptor mRNA was found to be 
slow in onset, whereas a much more rapid loss of receptor number 
was observed. This disparity suggests that the down-regulation 
induced by etorphine can occur both at the levels of receptor 
protein modification and receptor gene expression, and that the 
mechanisms of the two processes may be different. 
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1. Introduction 
efficacies for a given receptor type, it became clear that down- 
regulation of receptor number by pure agonists is a property 
of opiate receptors just as it is of adrenergic and other related 
receptors [8-10]. The recent success of a number of laboratories 
in cloning opiate receptors [11-17] provided the first opportu- 
nity to investigate some of the unique aspects of the mechanism 
of down-regulation f opiate receptors at the mRNA level. The 
delta opiate receptor found as the sole type in NG108-15 mouse 
neuroblastoma×rat glioma hybrid cells is coded for by a single 
gene in the parental mouse and yet exhibits at least 4 identifia- 
ble size species of mRNA in the cell line [17]. The study de- 
scribed here was designed to determine whether any or each of 
these RNA species is affected by the presence of opiate ag- 
onists. 
2. Materials and methods 
2.1. Preparation of membrane fractions 
NG108-15 membranes were prepared according to a previously de- 
scribed procedure [18] with slight modifications. Frozen-packed 
NG108-15 cells were suspended in 9 volumes of cold 0.32 M sucrose, 
10 mM Tris-HC1 pH 7.5, 5 mM MgC12, 10/.tM GTP, 50 mM NaC1, and 
disrupted with 25 strokes of a ground-glass ti sue-grinder. The homoge- 
nate was centrifuged at 20,000 rpm for 10 min at 4°C. The pellet was 
washed 3 times with the same buffer and resuspended in 0.32 M sucrose. 
Protein was measured by the method of Lowry et al. [19] with bovine 
serum albumin as the standard. 
Receptor activation can stimulate or inhibit a variety of cel- 
luar  processes which range from basic metabolic activities to 
certain highly specialized functions in differentiated tissues. 
A though receptors erve as regulators of these cellular activi- 
tk s, they are themselves subject o considerable r gulation. For 
m my G-protein-linked receptors, stimulation is followed by a 
pt riod of reduced responsiveness or desensitization in the con- 
ta ~ned presence of agonists, which usually involves ome com- 
bi aation of receptor phosphorylation, sequestration a d loss of 
re'eptor number, and uncoupling of the receptor from the 
et "ector [1-3]. In addition to this regulation at the protein level, 
tl-~ expression of the receptor gene itself can be modulated as 
a -onsequence of activation. In several cases mRNA levels for 
the receptor are rapidly reduced following stimulation, thereby 
ft rther contributing to the loss in receptor number and respon- 
si,,eness [4-7]. Clearly, this diversity of receptor egulation must 
depend on different cell signaling pathways which themselves 
se-ve to regulate gene expression. 
There is a long history of studies aimed at measuring the 
p,,ssible down-regulation f opiate receptors by their ligands. 
A:'ter some initial confusion caused by the unsuspected pres- 
el~ce of several types of opiate receptor and a range of agonist 
*t 'orresponding author. 
2.2. Ligand binding assay 
Delta opiate receptor numbers were measured inmembrane fractions 
by equilibrium radioligand binding analysis with 2 nM [3H]diprenor- 
phine as previously described [20]. Specific binding is defined as the 
difference between the amount of radioactive ligand bound in the pres- 
ence and absence of 10/.tM non-radioactive ligand after 10 min incuba- 
tion at 37°C. 
2.3. Northern hybridization analysis 
Six /.tg aliquots of poly(A) ÷ RNA [17] from differently treated 
NG108-15 cells were separated by electrophoresis on denaturing 1.2% 
agarose/3.0% formaldehyde gels. RNA was transferred to a nylon 
membrane and hybridization and washes were performed as described 
previously [17]. The blots were dried and subjected to autoradiographic 
exposure for 7 days. For the delta opiate receptor probe, a 980 bp 
HindIII to Eeo47III fragment of TB27 eDNA [17] was radiolabelled by 
the random hexamer-priming method. The glyceraldehyde 3-phosphate 
dehydrogenase (G3PDH) gene was used as a control for RNA loading 
with a probe corresponding to the mouse gene. For quantitation, films 
were scanned into a Macintosh computer and analyzed with NIH 
Image [21]. Integrated values were normalized to the G3PDH loading 
control. The results of the quantitation were confirmed by scanning els 
with a Fuji BAS3000 Bio-Imaging Analyzer. 
3. Results and discussion 
One of the interesting features of the delta opiate receptor 
system of NG108-15 cells that was discovered as a result of the 
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Fig. 1. Effect of treatment with various opiates on ~-opioid number in 
NG108-15 cell membranes. Cells were incubated in diprenorphine, 
etorphine, morphine, nalorphine, or vehicle for 4 days. All opiates were 
administrated at a dose of 10 #M. The membrane r ceptor number was 
measured by radioligand binding using [3H]diprenorphine as ligand. 
The data shown are representative of three separate experiments. The 
error bars show the S.E.M. of the measurements. 
recent cloning experiments i the fact that at least 4 sizes of 
mRNA are found, even though there is only a single gene in 
the mouse and probably in the cells as well. Several size species 
of mRNA presumably coding for the delta opiate receptor are 
found in the rat as well. What is the functional significance of 
these several species of RNA and how are their levels con- 
trolled? These questions prompted the present studies and are 
partially answered by the results. 
Challenging NG108-15 cells with various opiate receptor ag- 
onists and antagonists revealed that etorphine, a pure and pow- 
erful agonist reduced the number of receptor to 30% of control 
(Fig. 1). Diprenorphine and morphine, both of which are only 
partial agonists at the delta receptor [18], had much smaller 
effects, whereas nalorphine, an almost pure antagonist [8], had 
almost no effect on the number of receptors. To explore the 
basis of this loss of opiate receptors in the cells, we measured 
receptor mRNA levels by Northern hybridization analysis. 
NG108-15 cells expressed &-opiate receptor transcripts of 9.5, 
7.5, 4.4 and 3 kb ,  with the smallest mRNA as the most abun- 
dant (Fig. 2) [11,17]. These experiments showed that of the 
drugs tested, only etorphine caused a remarkable decline in the 
amounts of each of the transcripts. Furthermore, scanning den- 
sitometry of the blots showed that the differently sized tran- 
scripts were coordinately decreased, although there appears to 
be a preferential reduction of the larger transcripts. Interest- 
ingly. Jehab and Inturrisi showed that exposure of NG108 cells 
to the pure opiate antagonist, naloxone, produces a increase in 
the level of expression of opiate receptor mRNA [22]. 
Incubation of the cells with etorphine led to a time-dependent 
decrease in receptor density to 30% of control after 1 day which 
persisted for at least 4 days (Fig. 3). This decline was already 
evident after one hour of incubation but not after only several 
minutes (data not shown). In contrast to the rapid loss of opiate 
receptor numbers upon etorphine treatment, receptor mRNA 
levels were unchanged uring the first 2 days of treatment. 
Receptor mRNA levels only begin to decline on day 3 and the 
loss was maximal by day 5 (Fig. 4). 
Interestingly, each of the opiate receptor mRNA species is 
decreased after 3 or more days of culture with etorphine. This 
result strengthens the conclusion that each of these size classes 
of mRNA is indeed coding for the opiate receptor. The 
amounts of the larger members of this family of RNAs, those 
at 7.5 and 9.5 kb, are decreased to a significantly greater extent 
than are the smaller species. This result could suggest hat the 
rate of synthesis of the mRNA is decreased since the larger 
species would likely be the first products of transcription. How- 
ever, the rate of degradation of the transcripts could also be size 
dependant and direct measurements of opiate receptor mRNA 
turnover will be needed to answer these questions. 
Down-regulation of opiate receptor numbers is observed in 
NG108-15 cells after culture by agonists of high efficacy like 
etorphine, but not with agonists of only moderate or low effica- 
cies at this receptor, like morphine and diprenorphine [18] as 
shown in Fig. 1. The down-regulation bserved with etorphine 
is very rapid in onset as shown in Fig. 4 and is even observed 
after only 1 h of treatment (data not shown). In contrast to the 
very rapid loss of receptors measured by ligand binding, 
Changes in mRNA levels associated with culture in the pres- 
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Fig. 2. RNA blot analysis of 6-opioid receptor mRNA in NG108-15 
cells treated with various opiates. Poly(A) ÷ RNA was prepared from 
NG108-15 cells incubated for 4 days with no addition, diprenorphine 
(10 ,uM), etorphine (10 #M), morphine (10 #M), and nalorphine (10 
pM). Each lane contained 6mg of poly(A) ÷ RNA. Transcript size was 
determined by comparison to the mobility of RNA standards. 
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F~,. 3. Time course of the etorphine-induced decrease in6-opioid recep- 
te • number. NG 108-15 cells were incubated for the indicated times with 
11, ~tM etorphine. Cells were harvested and receptor number was deter- 
m ned by binding of [3H]diprenorphine on the membrane fraction. Data 
sl ~ ~wn are the mean S.E.M. of three experiments. 
e]ce of etorphine are slow in onset and occur over the course 
o! days rather than hours. Therefore, the initially rapid de- 
clzase in receptor numbers is likely to reflect a process unre- 
lated to the slower decrease in mRNA level. By analogy with 
other G-protein-coupled receptors, It is likely that the rapid 
down-regulation i duced by etorphine is due to a phosphoryl- 
ation and internalization of the receptors. How this process 
leads to the reduction of mRNA levels several days later is not 
known. The fact that down-regulation and reduction in mRNA 
levels are both correlated with agonist efficacy suggests that 
they are both initiated by interaction with G-proteins. 
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nl RNA levels (with day 0 defined as 100%) are expressed relative to G3PDH mRNA, since G3PDH expression isunaffected by etorphine treatment. 
I le experiment was performed two times with similar results. Shorter times of exposure were used to quantitate the G3PDH RNA, and the results 
~,~re confirmed by phosphoimager analysis. 
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